Analyst Group

Analyst Group Comment on Circio Holding’s Selection for Oral Presentation at ESGCT 2026

Källa: MFN
Positiv

Sammanfattning

Analyst Group kommenterar Circio Holdings urval för muntlig presentation vid ESGCT 2026, vilket ger synlighet bland potentiella partners. Förslaget om en ny styrelseledamot ses som en bekräftelse av teknologin. Kommande dataavläsningar under andra halvåret 2026 är avgörande för potentiella licensavtal.

Analys

Analyst Group bedömer att urvalet för presentation vid ESGCT ger Circio ökad synlighet hos potentiella partners, vilket är positivt i ett kritiskt skede av bolagets utveckling. Förslaget om en ny styrelseledamot, Dr. Dinah Sah, ses som en bekräftelse på bolagets teknologi från en erfaren expert inom gen- och RNA-terapi. De kommande dataavläsningarna under andra halvåret 2026, som täcker flera indikationer, är de viktigaste kortsiktiga händelserna och kan leda till det första licensavtalet.

Insikter

  • • ESGCT-presentationen är en viktig möjlighet att attrahera partners.
  • • Kommande dataavläsningar är avgörande för att nå ett första licensavtal.
  • • Ny styrelseledamot stärker teknologins trovärdighet.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 6th of August 2026, that it has been selected for an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) annual meeting in Hamburg, 27–30 October 2026, covering circVec for next-generation T-cell therapies. Separately, the Nomination Committee proposed Dr. Dinah Sah as a new Board Director on the 4th of August, for election at an Extraordinary General Meeting on the 25th of August.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 6th of August 2026, that it has been selected for an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) annual meeting in Hamburg, 27–30 October 2026, covering circVec for next-generation T-cell therapies. Separately, the Nomination Committee proposed Dr. Dinah Sah as a new Board Director on the 4th of August, for election at an Extraordinary General Meeting on the 25th of August.

In summary, Analyst Group views the ESGCT selection as providing Circio with visibility among prospective partners at a relevant point in its development, and the proposed board addition as an endorsement of the technology from an experienced gene and RNA therapy specialist. The H2-26 readouts, spanning in vivo CAR targeted T-cell delivery, wet AMD and heart disease-model efficacy and CNS PoC data, remain the most significant near-term events, and positive outcomes would represent progress in the direction of a first licensing agreement.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.